We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.4B
AUM Growth
-$1.33B
Cap. Flow
-$405M
Cap. Flow %
-9.2%
Top 10 Hldgs %
53.32%
Holding
82
New
7
Increased
5
Reduced
49
Closed
11

Top Buys

Rank Stock Value
1
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$220M
2
AUGX
Augmedix, Inc. Common Stock
AUGX
+$52.1M
3
TRDA icon
Entrada Therapeutics
TRDA
+$47.4M
4
CNC icon
Centene
CNC
+$26.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$100M
2
ARGX icon
argenx
ARGX
+$63.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$63.3M
4
SKIN icon
SkinHealth Systems
SKIN
+$61.9M
5
CLDX icon
Celldex Therapeutics
CLDX
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.18%
2 Consumer Staples 2.79%
3 Industrials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$291M
$758M 17.24%
12,957,222
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$262M 5.96%
22,716,086
+1,916,783
+9% +$21.4M
SNCE
3
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$247M 5.62%
+990,412
New +$220M
ARGX icon
4
argenx
ARGX
$64B
$183M 4.15%
521,643
-208,939
-29% -$63.6M
LIVN icon
5
LivaNova
LIVN
$4.43B
$180M 4.09%
2,057,178
-133,841
-6% -$11.2M
KYMR icon
6
Kymera Therapeutics
KYMR
$9.82B
$164M 3.74%
2,587,730
-205,978
-7% -$12M
ADCT icon
7
ADC Therapeutics
ADCT
$146M
$151M 3.42%
7,451,029
-78,300
-1% -$1.89M
BEAM icon
8
Beam Therapeutics
BEAM
$3.03B
$150M 3.42%
1,885,850
-89,156
-5% -$7.63M
KRYS icon
9
Krystal Biotech
KRYS
$10.4B
$127M 2.9%
1,820,898
-161,534
-8% -$9.4M
SKIN icon
10
SkinHealth Systems
SKIN
$89.1M
$123M 2.79%
5,082,805
-2,400,901
-32% -$61.9M
REPL icon
11
Replimune Group
REPL
$1.46B
$105M 2.38%
3,866,512
-211,600
-5% -$6.33M
ATRA icon
12
Atara Biotherapeutics
ATRA
$92.3M
$101M 2.31%
257,511
-1,140
-0.4% -$480K
IGMS
13
DELISTED
IGM Biosciences
IGMS
$97.8M 2.22%
3,334,355
-91,100
-3% -$4.53M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.72B
$85.6M 1.95%
2,958,284
-134,793
-4% -$4.09M
CLDX icon
15
Celldex Therapeutics
CLDX
$3.07B
$83.7M 1.9%
2,165,586
-877,712
-29% -$38.3M
ABSI icon
16
Absci
ABSI
$1.49B
$65.9M 1.5%
8,031,094
– –
VERV
17
DELISTED
Verve Therapeutics
VERV
$63M 1.43%
1,708,536
-160,494
-9% -$6.74M
RGNX icon
18
Regenxbio
RGNX
$638M
$62M 1.41%
1,897,223
-110,778
-6% -$3.77M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$61.3M 1.39%
8,258,345
– –
SRRK icon
20
Scholar Rock
SRRK
$7.04B
$60.8M 1.38%
2,447,926
-102,279
-4% -$2.82M
RPTX
21
DELISTED
Repare Therapeutics
RPTX
$58.8M 1.34%
2,789,496
+221,800
+9% +$5.22M
NVTA
22
DELISTED
Invitae Corporation
NVTA
$58.1M 1.32%
3,805,403
-1,512,074
-28% -$32.7M
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
$57.5M 1.31%
371,839
-215,535
-37% -$36.1M
STOK icon
24
Stoke Therapeutics
STOK
$2.04B
$53.9M 1.23%
2,246,668
-135,290
-6% -$3.23M
UNH icon
25
UnitedHealth
UNH
$353B
$52.5M 1.19%
104,488
-16,222
-13% -$7.34M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2021 Portfolio in Review

As of Q4 2021, Redmile Group held 82 positions worth $4.4B, down 23% from $5.73B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group withdrew a net $405M in Q4 2021, closing 11 positions and reducing 49 holdings. Its most notable exit was Amedisys, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Science 37 Holdings, Inc. Common Stock worth $247M.

  • Redmile Group's largest Q4 2021 buy was Science 37 Holdings, Inc. Common Stock: 990,412 shares worth $247M.
  • Redmile Group added most to Amicus Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Redmile Group's biggest Q4 2021 reduction was Jazz Pharmaceuticals, cutting an estimated $100M.
  • Redmile Group fully exited Amedisys in Q4 2021, selling an estimated $22.4M.
  • Redmile Group's ten largest holdings make up 53% of its $4.4B portfolio in Q4 2021.
  • Redmile Group opened 7 new positions and closed 11 in Q4 2021.
  • Redmile Group's portfolio value fell 23% quarter-over-quarter to $4.4B.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.